Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Proshares Trust (ZBIO) Accumulated Expenses (2023 - 2025)

Historic Accumulated Expenses for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to $45.4 million.

  • Zenas BioPharma's Accumulated Expenses rose 5898.15% to $45.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.4 million, marking a year-over-year increase of 5898.15%. This contributed to the annual value of $39.4 million for FY2024, which is 12749.91% up from last year.
  • As of Q3 2025, Zenas BioPharma's Accumulated Expenses stood at $45.4 million, which was up 5898.15% from $44.5 million recorded in Q2 2025.
  • Over the past 5 years, Zenas BioPharma's Accumulated Expenses peaked at $45.4 million during Q3 2025, and registered a low of $17.3 million during Q4 2023.
  • Its 3-year average for Accumulated Expenses is $33.9 million, with a median of $34.0 million in 2024.
  • In the last 5 years, Zenas BioPharma's Accumulated Expenses skyrocketed by 12749.91% in 2024 and then surged by 5898.15% in 2025.
  • Quarter analysis of 3 years shows Zenas BioPharma's Accumulated Expenses stood at $17.3 million in 2023, then soared by 127.5% to $39.4 million in 2024, then rose by 15.21% to $45.4 million in 2025.
  • Its Accumulated Expenses stands at $45.4 million for Q3 2025, versus $44.5 million for Q2 2025 and $28.2 million for Q1 2025.